Dry eye treatment for contact lens wearers
Part of Eyes & vision clinical trials.
This trial tests a treatment for dry eye in people who wear contact lenses. It may help if you've tried other dry eye treatments before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older
- You wear contact lenses
- You have tried previous dry eye treatments
- You are on a stable dose of certain medicines like antihistamines or birth control
- Your eyes have some staining from dryness
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment called Lacrifill to see if it helps reduce dry eye symptoms after cataract surgery. You would receive the treatment after your surgery to see if it improves comfort and eye health.
This trial tests a new eye drop for people who wear contact lenses and have dry eyes. The treatment may help reduce dryness and improve comfort while wearing lenses.
This study tests a temporary gel for the tear ducts that may help reduce dry eye symptoms after cataract surgery. If you qualify, you'll receive the gel in both eyes and be monitored to see if it improves comfort.
This study tests an eye drop called lifitegrast to see how well it helps dry eye disease. It also uses a special microscope to look at the surface of your eye. If you join, you might find a treatment that improves your dry eye symptoms.
This study tests an experimental eye drop for people with dry eye disease. It aims to see if the drops can reduce symptoms and signs of dry eye.
This trial tests a virtual reality headset (called Lacrima VR) to see if it can help relieve dry eye symptoms caused by meibomian gland dysfunction. It might be a non-drug option for people who have not found relief from other treatments.
Hear when a new Dry Eye trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.